<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02102646</url>
  </required_header>
  <id_info>
    <org_study_id>kk2013 MRI</org_study_id>
    <nct_id>NCT02102646</nct_id>
  </id_info>
  <brief_title>MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism</brief_title>
  <official_title>MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if androgen deprivation therapy in men with
      prostate cancer increases hepatic fat content and changes visceral/subcutaneous fat
      distribution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a substudy of the ongoing randomized trial entitled: Metabolic Changes Due to
      Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin
      (EudraCT number: 2013-002553-29). 20 consecutive patients are anticipated to participate
      regardless of assignment to either orchiectomy or triptorelin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hepatic fat content</measure>
    <time_frame>At baseline (within 4 weeks of commencement of androgen deprivation therapy) and after 24 weeks</time_frame>
    <description>Change in hepatic fat content measured by Magnetic Resonance Spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in visceral/subcutaneous fat mass</measure>
    <time_frame>At baseline (within 4 weeks of commencement of androgen deprivation therapy) and after 24 weeks</time_frame>
    <description>Changes in visceral and subcutaneous fat mass measured by Magnetic Resonance Imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between Hepatic fat content and baseline androgen status</measure>
    <time_frame>Androgen status measured before commencement of androgen deprivation therapy (ADT), hepatic fat content measured at baseline (within 1 month of commencing androgen deprivation therapy)</time_frame>
    <description>To investigate possible correlation between androgen status before commencing androgen deprivation therapy and hepatic fat content at baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Hypogonadism</condition>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Triptorelin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Triptorelin 22,5mg/24th week intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>orchiectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Androgen deprivation therapy by bilateral subcapsular orchiectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin</intervention_name>
    <description>Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.</description>
    <arm_group_label>Triptorelin</arm_group_label>
    <other_name>Pamorelin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Orchiectomy</intervention_name>
    <description>Androgen deprivation therapy by bilateral subcapsular orchiectomy</description>
    <arm_group_label>orchiectomy</arm_group_label>
    <other_name>Subcapsular orchiectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for inclusion are patients who are included in the already ongoing Randomised
             trial entitled: Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With
             Prostate Cancer: Orchiectomy vs. Triptorelin (EudraCT number: 2013-002553-29)

        Exclusion Criteria:

          -  Implanted devices or foreign metallic bodies incompatible with Magnetic Resonance
             Imaging.

          -  claustrophobia

          -  Severe Psychiatric disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter B Østergren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Herlev Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2014</study_first_submitted>
  <study_first_submitted_qc>March 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2014</study_first_posted>
  <last_update_submitted>October 27, 2015</last_update_submitted>
  <last_update_submitted_qc>October 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Peter Busch Østergren</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

